Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as an injection solution for subcutaneous use. It treats chemotherapy‑induced neutropenia, neutropenia associated with bone‑marrow transplantation, severe chronic neutropenia, and acute radiation syndrome in appropriate patients.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is used to stimulate neutrophil production in conditions that cause neutropenia.

- Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk. - Neutropenia associated with bone‑marrow transplantation: supports engraftment and shortens neutropenic period. - Severe chronic neutropenia: increases neutrophil counts to reduce infection susceptibility. - Acute radiation syndrome: accelerates hematologic recovery after radiation exposure.

Neupogen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bone pain: often reported at injection sites or generalized. - Injection site reactions: redness, swelling, or discomfort. - Fever: transient elevations in body temperature. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening. - Acute respiratory distress syndrome (ARDS): severe pulmonary reaction. - Severe allergic reactions: anaphylaxis or hypersensitivity requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform regular CBC to assess neutrophil response. - Assess for splenomegaly: evaluate spleen size before and during treatment. - Use caution in patients with sickle cell disease: increased risk of vaso‑occlusive events. - Avoid in patients with known hypersensitivity to filgrastim or any excipient. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other agents that affect the bone marrow or immune system.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may mask neutropenia and complicate monitoring. - Live vaccines: increased risk of vaccine‑related infection.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce the efficacy of filgrastim. - Antibiotics affecting bone marrow: monitor hematologic parameters closely. - Immunosuppressants such as azathioprine: may alter neutrophil response.